Paul M Coplan

Summary

Publications

  1. ncbi request reprint Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents
    Paul M Coplan
    Merck Research Laboratories, West Point, Pennsylvania, USA
    J Infect Dis 191:1427-34. 2005
  2. ncbi request reprint Public health. Regulatory challenges in microbicide development
    Paul M Coplan
    International Partnership for Microbicides, Silver Spring, MD 20910, USA
    Science 304:1911-2. 2004
  3. ncbi request reprint Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine
    Paul M Coplan
    Merck Research Laboratories, West Point, PA 19486, USA
    Clin Infect Dis 39:426-33. 2004
  4. ncbi request reprint Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors
    Paul M Coplan
    Department of Epidemiology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    AIDS Res Hum Retroviruses 19:449-55. 2003
  5. ncbi request reprint Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory
    Paul M Coplan
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Pain 5:344-56. 2004
  6. ncbi request reprint Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon
    Swati B Gupta
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    J Acquir Immune Defic Syndr 42:135-9. 2006
  7. ncbi request reprint Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials
    Carlos Rojas
    University of North Carolina, Chapel Hill, North Carolina, USA
    Pharmacoepidemiol Drug Saf 12:361-9. 2003
  8. pmc The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics
    David P Wilson
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Level 2, 376 Victoria Street, Sydney NSW 2010, Australia
    Proc Natl Acad Sci U S A 105:9835-40. 2008

Detail Information

Publications8

  1. ncbi request reprint Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents
    Paul M Coplan
    Merck Research Laboratories, West Point, Pennsylvania, USA
    J Infect Dis 191:1427-34. 2005
    ..Therefore, we quantified the cross-clade reactivity, among unvaccinated individuals, of anti-HIV-1 T cell responses to the infecting HIV-1 clade relative to other major circulating clades...
  2. ncbi request reprint Public health. Regulatory challenges in microbicide development
    Paul M Coplan
    International Partnership for Microbicides, Silver Spring, MD 20910, USA
    Science 304:1911-2. 2004
  3. ncbi request reprint Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine
    Paul M Coplan
    Merck Research Laboratories, West Point, PA 19486, USA
    Clin Infect Dis 39:426-33. 2004
    ..We examined the impact of indinavir on quality of life in participants from this study...
  4. ncbi request reprint Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors
    Paul M Coplan
    Department of Epidemiology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    AIDS Res Hum Retroviruses 19:449-55. 2003
    ..Although studies with a longer duration of PI therapy are in progress to assess whether a later increase in MI incidence occurs, our analysis did not demonstrate a dramatic increase in MI risk during the first year of PI therapy...
  5. ncbi request reprint Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory
    Paul M Coplan
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Pain 5:344-56. 2004
    ..These findings support the validity and utility of the ZBPI, the definition of PHN, and the severity-duration measure of the burden of HZ illness...
  6. ncbi request reprint Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon
    Swati B Gupta
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    J Acquir Immune Defic Syndr 42:135-9. 2006
    ..Substantial cross-clade cell-mediated immune responses in Botswana and Cameroon confirm previous findings in a larger, more genetically diverse collection of HIV-1 samples...
  7. ncbi request reprint Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials
    Carlos Rojas
    University of North Carolina, Chapel Hill, North Carolina, USA
    Pharmacoepidemiol Drug Saf 12:361-9. 2003
    ....
  8. pmc The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics
    David P Wilson
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Level 2, 376 Victoria Street, Sydney NSW 2010, Australia
    Proc Natl Acad Sci U S A 105:9835-40. 2008
    ..Interventions that use ARV-based microbicides could have surprising consequences...